Pfizer 2011 Annual Review | Pfizer: the world's largest research-based pharmaceutical company

Investments in Health

We offer a strategic, coordinated approach to improve access to medicines and health care for underserved patients around the world. Our social investments focus on effective and sustainable health care delivery while empowering our colleagues, strengthening our stakeholder relationships, and ultimately having a positive impact on society and our business.

Programs Description Target Region Impact
Pfizer Helpful Answers Provide Pfizer medicines for free or at a savings to patients who qualify U.S. Enabled 3.8 million uninsured or underinsured patients to get access to more than 40 million Pfizer prescriptions from 2007–2011 (Pfizer Helpful Answers)
Infectious Disease Institute Build capacity for prevention, treatment, training, research and clinical services in Uganda Africa Provide ongoing care and treatment to more than 37,000 patients, with outreach to 376,000 individuals; ~6,800 health care workers from 27 countries received training in HIV/AIDS since program inception
Global Health Fellows Improve access, quality and efficiency of health care for underserved populations through individual and team volunteer assignments Global—Africa, Asia, Latin America, Europe, U.S. Develop innovative public health models that address challenges in cancer and tobacco control, in an effort to combat noncommunicable diseases globally
International Trachoma Initiative Eliminate trachoma by 2020 through the donation of Zithromax and an integrated public health strategy Africa, Asia, Latin America More than 285 million patients treated with Zithromax to date
Mobilize Against Malaria Educate treatment providers and patients to improve malaria treatment Ghana, Kenya, Senegal Enabled more than 1,000 licensed chemical sellers to provide better malaria education to over 20,000 people in Ghana
Global Health Partnership Strengthen innovative public health partnerships that address challenges in cancer and tobacco control, in support of the noncommunicable diseases movement Global—47 countries in Asia, Latin America, Europe, Africa and U.S. More than 97,000 patients served and 266,000 health care workers trained from 2008–2011
Diflucan Partnership Program Donate Diflucan for treatment of two fungal opportunistic infections associated with HIV/AIDS 63 countries in Africa, Asia, Latin America Provided over $1.2 billion in medicine to sites in 63 countries to date

* Data on file